Stock listing

NASDAQ:CGEN Compugen Ltd. Stock

Home listing (NASDAQ) of Compugen Ltd.

Follow Compugen Ltd. into a list and get an email when it puts out news.

Share price · NASDAQ:CGEN

$1.84 USD -0.12 (-6.1%)

Close on Nov 20, 2026

Past year +21.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.81 – $1.88 USDNov 20, 2026
Volume
188,249 sharesNov 20, 2026
Market cap
$174.3M USDAt the close on Nov 20, 2026 · price × 94.72M shares outstanding
52-week range
$1.43 – $3.24 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$552,185 USDMedian day 198,865 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Compugen Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CGEN · Home$1.84 USD-0.12 (-6.1%)188,249$1.85$1.875$1.81$1.96Close on Nov 20, 2026
TASE:CGEN645.00 ILA (agorot)-11.10 (-1.7%)44,952650.00654.90631.20656.10Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CGEN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.84-0.12-6.1%$1.85$1.875$1.81188,249
$1.96-0.06-3.0%$2.00$2.025$1.96145,988
$2.02-0.02-1.0%$1.99$2.05$1.98197,679
$2.04-0.06-2.9%$2.06$2.07$2.00250,429
$2.10-0.02-0.9%$2.11$2.12$2.035209,585
$2.12+0.03+1.4%$2.04$2.14$2.04190,239
$2.090.000.0%$2.09$2.115$2.07210,994
$2.09-0.05-2.3%$2.13$2.14$2.03214,912
$2.14+0.18+9.2%$1.96$2.15$1.96290,494
$1.96+0.04+2.1%$1.88$1.97$1.88183,990
$1.92-0.11-5.4%$2.00$2.00$1.865299,927
$2.03+0.02+1.0%$2.03$2.05$1.98202,920
$2.01+0.03+1.5%$1.98$2.04$1.98212,668
$1.980.000.0%$1.97$1.995$1.955151,472
$1.98-0.06-2.9%$2.02$2.02$1.92255,458
$2.04+0.03+1.5%$2.02$2.07$2.00142,900
$2.01+0.04+2.0%$1.96$2.01$1.96149,264
$1.97+0.095+5.1%$1.92$1.97$1.88131,407
$1.875-0.065-3.4%$1.95$1.975$1.87334,463
$1.94-0.02-1.0%$1.97$1.97$1.89148,020
$1.96-0.16-7.5%$2.11$2.14$1.92285,545
$2.12-0.02-0.9%$2.15$2.20$2.105186,969
$2.14+0.17+8.6%$1.96$2.18$1.96923,298
$1.97+0.01+0.5%$1.97$1.995$1.95159,251
$1.96-0.12-5.8%$2.08$2.09$1.93173,435
$2.08+0.08+4.0%$2.02$2.13$2.02200,141
$2.00+0.02+1.0%$2.01$2.02$1.95378,142
$1.98-0.09-4.3%$2.09$2.09$1.96223,637
$2.07-0.06-2.8%$2.13$2.13$2.0786,472
$2.13+0.01+0.5%$2.13$2.13$2.08123,363
$2.12-0.03-1.4%$2.14$2.16$2.04243,151
$2.15-0.07-3.2%$2.22$2.225$2.13201,813
$2.22-0.09-3.9%$2.32$2.331$2.205265,380
$2.310.000.0%$2.30$2.32$2.25198,865
$2.31-0.03-1.3%$2.34$2.38$2.305113,986
$2.34-0.04-1.7%$2.39$2.435$2.33173,346
$2.38+0.03+1.3%$2.35$2.41$2.345118,236
$2.35+0.02+0.9%$2.32$2.35$2.30117,182
$2.33-0.05-2.1%$2.34$2.345$2.31594,071
$2.38+0.01+0.4%$2.40$2.42$2.34577,756
$2.37+0.03+1.3%$2.34$2.375$2.325111,364
$2.34-0.15-6.0%$2.45$2.47$2.305288,332
$2.49+0.055+2.3%$2.46$2.495$2.405230,978
$2.435-0.055-2.2%$2.45$2.495$2.42217,393
$2.49+0.03+1.2%$2.47$2.49$2.45128,001
$2.46+0.05+2.1%$2.42$2.47$2.42122,757
$2.410.000.0%$2.41$2.47$2.40117,641
$2.41-0.07-2.8%$2.49$2.49$2.37330,761
$2.48+0.01+0.4%$2.42$2.54$2.42144,471
$2.47+0.01+0.4%$2.47$2.496$2.43162,163
$2.46-0.02-0.8%$2.48$2.51$2.44206,983
$2.48-0.08-3.1%$2.55$2.55$2.46293,782
$2.56-0.03-1.2%$2.55$2.625$2.55192,901
$2.59+0.035+1.4%$2.54$2.61$2.54199,695
$2.555-0.075-2.9%$2.64$2.66$2.535163,617
$2.63+0.04+1.5%$2.56$2.63$2.555127,918
$2.59+0.03+1.2%$2.56$2.60$2.53168,925
$2.56-0.04-1.5%$2.63$2.63$2.52175,117
$2.60-0.16-5.8%$2.72$2.72$2.58228,794
$2.76-0.08-2.8%$2.86$2.86$2.72301,266
$2.84-0.03-1.0%$2.83$2.935$2.80667,034
$2.87+0.28+10.8%$2.60$2.91$2.59799,789
$2.59-0.025-1.0%$2.58$2.605$2.49218,360
$2.615-0.035-1.3%$2.64$2.77$2.61447,161
$2.65+0.21+8.6%$2.54$2.68$2.47993,918
Ticker
NASDAQ:CGEN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Compugen Ltd. news

Compugen Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 195 in all · newest Nov 10, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Nov 9, 2026
Decks
21 decks · latest Oct 5, 2026

Where Compugen Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:CGEN · Home listing · This pageNASDAQUnited StatesUSD
TASE:CGENTASEIsraelILA
BOATS:CGENBOATSUnited StatesUSD
Tradegate:CW9TradegateGermanyEUR

Valuation

EV/sales 0.8× against a median of 15.6×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$59.55M USD
P/E
4.8×
EV/sales
0.8×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.1×
Gross margin
86.2%
Operating margin
41.3%
Net margin
47.9%
Debt to equity
0.0×
Beta vs S&P 500
1.49

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Compugen Ltd. · NASDAQ:CGENUS$174.3MUS$59.55M4.8×0.8×n/a2.1×47.9%0.0×1.49
Whitehawk Therapeutics, Inc. · NASDAQ:WHWKUS$181.2MUS$11.70Mn/an/an/a1.1×n/a0.0×1.35
Sol-Gel Technologies Ltd. · NASDAQ:SLGLUS$180.6MUS$137.0Mn/a95.4×n/a4.2×n/a0.0×0.67
Tanvex BioPharma, Inc. · TWSE:6541US$180.5MUS$225.7Mn/a11.3×n/a1.2×−222.8%0.4×n/a
Korro Bio, Inc. · NASDAQ:KRROUS$179.4MUS$74.36Mn/a57.6×n/a2.0×n/a0.0×1.46
Vogenx Inc · NASDAQ:VOGXUS$176.3MUS$94.21Mn/an/an/a2.1×n/a0.0×n/a
MediWound Ltd. · NASDAQ:MDWDUS$175.5MUS$155.9Mn/a15.6×n/a5.5×−235.0%0.3×0.64
Nanexa AB · OMXSTO:NANEXAUS$175.1MUS$170.1Mn/a51.4×n/a13.5×−72.5%0.0×n/a
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H · HKEX:2591US$170.8MUS$39.93Mn/a2.1×n/a1.2×−259.6%0.2×n/a
Entrada Therapeutics, Inc. · NASDAQ:TRDAUS$170.3MUS$24.60Mn/a6.2×n/a0.9×n/a0.2×1.43
SinoMab Bioscience Ltd. · HKEX:3681US$166.3MUS$172.4Mn/an/an/a3.1×n/a0.7×n/a
Median of the othersUS$175.9MUS$115.6M15.6×2.1×−228.9%0.1×1.35

Forecasts

5 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
4.80 USD · Analysts' mean
EPS, year to Dec 2026
-0.29 · 2 analysts
Revenue, year to Dec 2026
9.56M · 4 analysts

Team and board

Officers

OfficerRole
Eran OphirPresident and CEO
David SilbermanChief Financial Officer
Pierre FerreChief Operating Officer
Eran Ben DorGeneral Counsel and Corporate Secretary
Lindsey TrickettHead of Investor Relations and Corporate Communications
Yvonne NaughtonPh.D.Vice President, Head of Investor Relations and Corporate CommunicationsEmail
Dorit AmitayVice President, Human Resources
Sharon Kredo-RussoSenior Vice President, Research & Discovery
Zurit LevineSenior Vice President, Business Development
Anat Cohen-DayagExecutive Chair
Eran PerryManaging Director and Chairman of the Investment Committee, MII Fund & Labs
Michelle MahlerChief Medical Officer

Board

DirectorRole
Anat Cohen-DayagExecutive Chair
Eran OphirPresident and CEO
Michele HolcombDirector

Events

Next results
Mar 1, 2027 (expected)

Calls

CallWhenStatus
Compugen (NASDAQ:CGEN) Q3 2026 Earnings CallMon, Nov 09, 2026 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q2 2026 Earnings CallMon, Aug 03, 2026 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q1 2026 Earnings CallMon, May 18, 2026 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q4 2025 Earnings CallMon, Mar 02, 2026 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q3 2025 Earnings CallThu, Nov 20, 2025 · 5:00 PM ETReplay
Compugen (NASDAQ:CGEN) Q2 2025 Earnings CallWed, Aug 06, 2025 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q1 2025 Earnings CallMon, May 19, 2025 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q4 2024 Earnings CallTue, Mar 04, 2025 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q2 2024 Earnings CallTue, Aug 06, 2024 · 8:30 AM ETReplay
All 26 calls
CallWhenStatus
Compugen (NASDAQ:CGEN) Q1 2024 Earnings CallMon, May 20, 2024 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q4 2023 Earnings CallTue, Mar 05, 2024 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q3 2023 Earnings CallTue, Nov 07, 2023 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q2 2023 Earnings CallMon, Aug 07, 2023 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q1 2023 Earnings CallMon, May 15, 2023 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q4 2022 Earnings CallMon, Feb 27, 2023 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q3 2022 Earnings CallMon, Nov 14, 2022 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q2 2022 Earnings CallThu, Aug 04, 2022 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q4 2021 Earnings CallThu, Feb 24, 2022 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q3 2021 Earnings CallFri, Nov 12, 2021 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q2 2021 Earnings CallWed, Jul 28, 2021 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q1 2021 Earnings CallThu, May 13, 2021 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q4 2020 Earnings CallThu, Feb 25, 2021 · 7:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q3 2020 Earnings CallThu, Nov 05, 2020 · 7:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q2 2020 Earnings CallThu, Jul 30, 2020 · 8:30 AM ETReplay
Compugen (NASDAQ:CGEN) Q1 2020 Earnings CallWed, May 06, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+9.2%
Q2 2026Aug 3, 2026 · Before open+1.3%
Q1 2026May 18, 2026 · Before open+4.0%
Q4 2025Mar 2, 2026 · Before open+24.3%
Q3 2025Nov 10, 2025 · Before open+3.1%
Q2 2025Aug 6, 2025 · Before open0.0%
Q1 2025May 19, 2025 · Before open0.0%
Q4 2024Mar 4, 2025 · Before open−7.2%
Q3 2024Nov 12, 2024 · Before open−8.1%
Q2 2024Aug 6, 2024 · Before open+4.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 20, 2024 · Before open−17.5%
Q4 2023Mar 5, 2024 · Before open−13.6%
Q3 2023Nov 7, 2023 · Before open−5.8%
Q2 2023Aug 7, 2023 · Before open−8.0%
Q1 2023May 15, 2023 · Before open+10.0%
Q4 2022Feb 27, 2023 · Before open+2.2%
Q3 2022Nov 14, 2022 · Before open−9.3%
Q2 2022Aug 4, 2022 · Before open−4.3%
Q1 2022May 16, 2022 · Before open+1.6%
Q4 2021Feb 24, 2022 · Before open+6.2%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (October 2026)Technical33 slidesOct 5, 2026
Q2 2026 Earnings PresentationEarnings7 slidesAug 3, 2026
Q4 2025 Earnings PresentationEarnings50 slidesMar 2, 2026
Technical Presentation (May 2023)Technical19 slidesMay 23, 2023
Investor Presentation (May 2023)Investor deck7 slidesMay 15, 2023
CIMT Annual Meeting 2023Conference16 slidesMay 5, 2023
TIGIT Axis Therapies Digital Summit 2022Conference31 slidesDec 8, 2022
Keystone Symposium, Decoding the Cancer Immunity Interactome 2022Conference22 slidesMarch 2022
Investor Presentation (February 2022)Investor deck33 slidesFebruary 2022
Q3 2021 Earnings PresentationEarnings12 slidesNov 12, 2021
All 21 decks
DeckKindSlidesDate
SITC Targets for Cancer Immunotherapy: A Deep Dive Seminar Series (June 2021)Conference19 slidesJun 29, 2021
Investor Presentation (November 2020)Investor deck36 slidesNovember 2020
Technical Presentation (April 2020)Technical24 slidesApr 27, 2020
Investor Presentation (June 2016)Investor deck47 slidesJune 2016
Investor Presentation (September 2015)Investor deck37 slidesSeptember 2015
Investor Presentation (March 2006)Investor deck24 slidesMarch 2006
Investor Presentation (May 2005)Investor deck29 slidesMay 2005
R&D Leaders' Forum Autumn 2004Conference26 slidesOctober 2004
Bio-Tech Israel 2004Conference17 slidesMay 5, 2004
Investor Presentation (February 2004)Investor deck28 slidesFebruary 2004
RDLeaders Forum 2004Conference30 slides2004

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue72.8M27.9M33.5M7.50M6.00M2.00M017.8M0712.0K
Cost of revenue9.25M7.93M2.00M975.0K680.0K60.0K989.0K1.03M1.59M223.0K
Gross profit63.5M19.9M31.5M6.53M5.32M1.94M-989.0K16.8M-1.59M489.0K
Research and development22.8M24.8M34.5M30.6M28.7M22.8M19.8M30.3M28.6M24.5M
Selling, general and administrative8.89M9.44M9.73M10.3M10.9M9.80M8.41M8.04M7.63M7.35M
Operating income31.3M-14.9M-13.0M-35.4M-35.1M-31.5M-28.9M-23.2M-37.4M-32.6M
Depreciation and amortization475.0K486.0K476.0K482.0K461.0K715.0K989.0K1.39M1.59M1.48M
EBITDA31.8M-14.4M-12.5M-34.9M-34.6M-30.8M-27.9M-21.8M-35.8M-31.1M
Interest expense34.0K31.0K27.0K869.0K1.72M1.81M620.0K508.0K705.0K
Income before tax35.4M-9.71M-9.78M-33.6M-34.2M-29.7M-28.1M-22.6M-37.1M-31.5M
Income tax54.0K4.52M8.97M58.0K00-722.0K-1.26M-678.0K20.0K
Net income35.3M-14.2M-18.8M-33.7M-34.2M-29.7M-27.3M-22.6M-37.1M-31.5M
Earnings per share, basic0.38-0.16-0.21-0.39-0.41-0.37-0.43-0.41-0.72-0.62
Earnings per share, diluted0.38-0.16-0.21-0.39-0.41-0.37-0.43-0.41-0.72-0.62

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents90.6M18.2M13.9M11.1M7.80M7.14M9.19M5.86M25.5M9.71M
Short-term investments9.28M23.6M11.7M0109.2M116.6M34.0M39.2M3.92M50.8M
Receivables294.0K061.0M0188.0K2.00M341.0K167.0K741.0K82.0K
Inventory-72.6M-5.99M-119.3M-780.0K-1.34M-1.74M-2.06M
Current assets148.0M106.0M114.6M86.1M123.2M129.1M45.0M46.6M31.2M62.7M
Property, plant and equipment681.0K852.0K1.22M1.53M1.66M1.71M2.34M3.37M4.65M5.96M
Total assets156.6M115.0M121.3M94.2M132.2M138.3M53.8M53.2M38.7M71.1M
Accounts payable2.35M1.84M3.50M1.77M4.62M1.41M1.09M2.95M3.44M1.27M
Current liabilities22.6M20.2M26.3M11.9M17.1M10.5M6.82M9.99M6.19M4.74M
Long-term debt3.00M
Total debt2.96M2.91M1.35M1.93M2.75M3.17M3.58M
Total liabilities53.8M60.1M55.8M16.5M25.5M18.5M15.4M15.9M9.45M7.62M
Shareholders' equity102.7M54.9M65.6M77.7M106.7M119.8M38.3M37.2M29.3M63.5M
Shares outstanding94.6M89.5M89.2M86.6M86.4M83.7M67.9M59.8M51.3M51.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations31.6M49.6M-35.9M-34.1M-22.7M-28.3M-27.9M-13.3M-30.7M-19.8M
Capital spending-306.0K-118.0K-172.0K-477.0K-292.0K-166.0K-155.0K-158.0K-385.0K-2.60M
Free cash flow31.3M49.5M-36.1M-34.6M-23.0M-28.5M-28.0M-13.4M-31.0M-22.4M
Cash from investing30.0M-46.3M35.5M37.1M6.62M-82.2M5.33M-35.2M46.3M16.2M
Cash from financing10.6M554.0K3.08M353.0K16.8M108.5M25.9M28.4M201.0K2.46M
Share buybacks25.9M28.4M201.0K2.46M
Change in cash72.4M3.97M2.83M2.91M704.0K-2.03M3.37M-20.1M15.8M-1.15M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 9, 2026Current reportSEC
6-K · Report of a foreign issuerSep 10, 2026Current reportSEC
UPLOAD · Letter from the SECAug 4, 2026Other filingsSEC
6-K · Report of a foreign issuerAug 3, 2026Current reportSEC
6-K · Report of a foreign issuerAug 3, 2026Current reportSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
CORRESP · Letter to the SECJul 28, 2026Other filingsSEC
UPLOAD · Letter from the SECJul 17, 2026Other filingsSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 9, 2026Other filingsSEC
CORRESP · Letter to the SECJun 4, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 21, 2026Other filingsSEC
F-3 · Registration statementMay 18, 2026Offer documentSEC
6-K · Report of a foreign issuerMay 18, 2026Current reportSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4/A · Change in ownership, amendedApr 15, 2026Insider tradeSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
144 · Notice of proposed saleApr 13, 2026Other filingsSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
144 · Notice of proposed saleMar 26, 2026Other filingsSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
20-F · Annual reportMar 2, 2026Annual reportSEC
6-K · Report of a foreign issuerMar 2, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 12, 2026Current reportSEC
6-K · Report of a foreign issuerDec 17, 2025Current reportSEC
6-K · Report of a foreign issuerNov 10, 2025Current reportSEC
6-K · Report of a foreign issuerOct 14, 2025Current reportSEC
6-K · Report of a foreign issuerSep 17, 2025Current reportSEC
6-K · Report of a foreign issuerAug 6, 2025Current reportSEC
6-K · Report of a foreign issuerAug 6, 2025Current reportSEC
6-K · Report of a foreign issuerJul 21, 2025Current reportSEC
6-K · Report of a foreign issuerMay 19, 2025Current reportSEC
6-K · Report of a foreign issuerMay 13, 2025Current reportSEC
20-F · Annual reportMar 4, 2025Annual reportSEC
6-K · Report of a foreign issuerMar 4, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJan 8, 2025Current reportSEC
6-K · Report of a foreign issuerNov 27, 2024Current reportSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerNov 5, 2024Current reportSEC
6-K · Report of a foreign issuerSep 13, 2024Current reportSEC
6-K · Report of a foreign issuerAug 6, 2024Current reportSEC
6-K · Report of a foreign issuerAug 5, 2024Current reportSEC
6-K · Report of a foreign issuerJul 29, 2024Current reportSEC
6-K · Report of a foreign issuerMay 30, 2024Current reportSEC
6-K · Report of a foreign issuerMay 20, 2024Current reportSEC
6-K · Report of a foreign issuerMay 15, 2024Current reportSEC
20-F · Annual reportMar 5, 2024Annual reportSEC
6-K · Report of a foreign issuerMar 5, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 15, 2024Current reportSEC
6-K · Report of a foreign issuerJan 8, 2024Current reportSEC
6-K · Report of a foreign issuerDec 19, 2023Current reportSEC
6-K · Report of a foreign issuerNov 7, 2023Current reportSEC
6-K · Report of a foreign issuerNov 6, 2023Current reportSEC
6-K · Report of a foreign issuerNov 3, 2023Current reportSEC
6-K · Report of a foreign issuerSep 21, 2023Current reportSEC
UPLOAD · Letter from the SECAug 24, 2023Other filingsSEC
CORRESP · Letter to the SECAug 23, 2023Other filingsSEC
20-F/A · Annual report, amendedAug 23, 2023Annual reportSEC
UPLOAD · Letter from the SECAug 15, 2023Other filingsSEC
6-K · Report of a foreign issuerAug 7, 2023Current reportSEC
6-K · Report of a foreign issuerAug 7, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveJun 28, 2023Other filingsSEC
CORRESP · Letter to the SECJun 23, 2023Other filingsSEC
F-3/A · Registration statement, amendedJun 23, 2023Offer documentSEC
6-K · Report of a foreign issuerJun 22, 2023Current reportSEC
6-K · Report of a foreign issuerJun 13, 2023Current reportSEC
6-K · Report of a foreign issuerJun 5, 2023Current reportSEC
6-K · Report of a foreign issuerMay 15, 2023Current reportSEC
6-K · Report of a foreign issuerMay 3, 2023Current reportSEC
CORRESP · Letter to the SECApr 14, 2023Other filingsSEC
F-3/A · Registration statement, amendedApr 14, 2023Offer documentSEC
UPLOAD · Letter from the SECApr 5, 2023Other filingsSEC
F-3 · Registration statementMar 30, 2023Offer documentSEC
6-K · Report of a foreign issuerMar 10, 2023Current reportSEC
6-K · Report of a foreign issuerMar 6, 2023Current reportSEC
20-F · Annual reportFeb 28, 2023Annual reportSEC
6-K · Report of a foreign issuerFeb 27, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 14, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 3, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerJan 31, 2023Current reportSEC
424B5 · ProspectusJan 31, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 6, 2022Current reportSEC
6-K · Report of a foreign issuerDec 2, 2022Current reportSEC
6-K · Report of a foreign issuerDec 1, 2022Current reportSEC
6-K · Report of a foreign issuerNov 16, 2022Current reportSEC
6-K · Report of a foreign issuerNov 14, 2022Current reportSEC
6-K · Report of a foreign issuerNov 7, 2022Current reportSEC
6-K · Report of a foreign issuerNov 2, 2022Current reportSEC
6-K · Report of a foreign issuerSep 22, 2022Current reportSEC
6-K · Report of a foreign issuerSep 15, 2022Current reportSEC
6-K · Report of a foreign issuerSep 12, 2022Current reportSEC
S-8 · Registration statement for employee plansAug 4, 2022Offer documentSEC
6-K · Report of a foreign issuerAug 4, 2022Current reportSEC
6-K · Report of a foreign issuerAug 4, 2022Current reportSEC
6-K · Report of a foreign issuerAug 4, 2022Current reportSEC
6-K · Report of a foreign issuerAug 4, 2022Current reportSEC
6-K · Report of a foreign issuerMay 16, 2022Current reportSEC
6-K · Report of a foreign issuerMay 10, 2022Current reportSEC
20-F/A · Annual report, amendedFeb 28, 2022Annual reportSEC
20-F · Annual reportFeb 28, 2022Annual reportSEC
6-K · Report of a foreign issuerFeb 24, 2022Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 4, 2022Big-stake noticeSEC
DNov 22, 2021Other filingsSEC
SC 13G · Big-stake noticeNov 19, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2021Current reportSEC
6-K · Report of a foreign issuerNov 12, 2021Current reportSEC
6-K · Report of a foreign issuerSep 2, 2021Current reportSEC
6-K · Report of a foreign issuerJul 29, 2021Current reportSEC
6-K · Report of a foreign issuerJul 28, 2021Current reportSEC
6-K · Report of a foreign issuerJun 8, 2021Current reportSEC
6-K · Report of a foreign issuerMay 13, 2021Current reportSEC
20-F · Annual reportFeb 25, 2021Annual reportSEC
6-K · Report of a foreign issuerFeb 25, 2021Current reportSEC
6-K · Report of a foreign issuerFeb 22, 2021Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 16, 2021Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 11, 2021Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 5, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerDec 23, 2020Current reportSEC
6-K · Report of a foreign issuerDec 10, 2020Current reportSEC
S-8 · Registration statement for employee plansDec 10, 2020Offer documentSEC
6-K · Report of a foreign issuerNov 5, 2020Current reportSEC
SC 13G/A · Big-stake notice, amendedOct 9, 2020Big-stake noticeSEC
6-K · Report of a foreign issuerSep 17, 2020Current reportSEC
6-K · Report of a foreign issuerSep 8, 2020Current reportSEC
EFFECT · Notice that a registration is effectiveAug 10, 2020Other filingsSEC
CORRESP · Letter to the SECAug 5, 2020Other filingsSEC
UPLOAD · Letter from the SECAug 5, 2020Other filingsSEC
6-K · Report of a foreign issuerAug 5, 2020Current reportSEC
F-3 · Registration statementJul 30, 2020Offer documentSEC
S-8 · Registration statement for employee plansJul 30, 2020Offer documentSEC
6-K · Report of a foreign issuerJul 30, 2020Current reportSEC
6-K · Report of a foreign issuerJun 1, 2020Current reportSEC
6-K · Report of a foreign issuerMay 27, 2020Current reportSEC
6-K · Report of a foreign issuerMay 6, 2020Current reportSEC
6-K · Report of a foreign issuerApr 27, 2020Current reportSEC
6-K · Report of a foreign issuerApr 15, 2020Current reportSEC
6-K · Report of a foreign issuerApr 6, 2020Current reportSEC
6-K · Report of a foreign issuerMar 17, 2020Current reportSEC
6-K · Report of a foreign issuerMar 13, 2020Current reportSEC
424B5 · ProspectusMar 12, 2020Offer documentSEC
6-K · Report of a foreign issuerMar 12, 2020Current reportSEC
6-K · Report of a foreign issuerMar 11, 2020Current reportSEC
424B5 · ProspectusMar 11, 2020Offer documentSEC
6-K · Report of a foreign issuerMar 9, 2020Current reportSEC
20-F/A · Annual report, amendedFeb 27, 2020Annual reportSEC
20-F · Annual reportFeb 24, 2020Annual reportSEC
6-K · Report of a foreign issuerFeb 20, 2020Current reportSEC
6-K · Report of a foreign issuerFeb 20, 2020Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2020Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2020Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2020Big-stake noticeSEC
6-K · Report of a foreign issuerJan 9, 2020Current reportSEC
6-K · Report of a foreign issuerNov 12, 2019Current reportSEC
6-K · Report of a foreign issuerNov 5, 2019Current reportSEC
6-K · Report of a foreign issuerNov 4, 2019Current reportSEC
6-K · Report of a foreign issuerSep 19, 2019Current reportSEC
SC 13G · Big-stake noticeSep 9, 2019Big-stake noticeSEC
SC 13G · Big-stake noticeSep 6, 2019Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveAug 13, 2019Other filingsSEC
CORRESP · Letter to the SECAug 8, 2019Other filingsSEC
UPLOAD · Letter from the SECAug 7, 2019Other filingsSEC
F-3 · Registration statementAug 5, 2019Offer documentSEC

This page holds 200 of 608 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Compugen Ltd.’s releases

Common shares
94,724,146
Fully diluted
94,724,146

Fully diluted

LineShares
Common shares94,724,146

Share count over time

CountShares
Nov 22, 202694,724,146

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
Nomura Healthcare Fund1.02MUS$2.18MJun 30, 2026
ARK Israel Innovative Technology ETF888KUS$2.06MJul 31, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF346KUS$741KJun 30, 2026
Taylor Frigon Core Growth Fund243KUS$639KMay 31, 2026
International Core Equity 2 Portfolio71,228US$160KJul 31, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF63,080US$135KJun 30, 2026
Fidelity Nasdaq Composite Index Fund56,738US$149KMay 31, 2026
The Continental Small Company Series19,304US$43,432Jul 31, 2026
International Social Core Equity Portfolio18,907US$42,538Jul 31, 2026
Dfa International Small Cap Value Portfolio16,001US$36,000Jul 31, 2026
All 15 holders
HolderSharesValueAs of
International Sustainability Core 1 Portfolio14,192US$31,930Jul 31, 2026
International Vector Equity Portfolio13,486US$30,342Jul 31, 2026
World ex U.S. Core Equity Portfolio10,412US$23,426Jul 31, 2026
Dimensional VA International Small Portfolio8,383US$18,861Jul 31, 2026
Blackstone Alternative Multi-Strategy Fund4,200US$8,988Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Levine Zurit
Officer: SVP, Business Development
Sale1,875USD 2.50US$4,688Jul 9, 2026
Ophir Eran
Director, Officer: President and CEO
Sale5,000USD 3.20US$16,000Apr 24, 2026
Levine Zurit
Officer: SVP, Business Development
Sale2,000USD 3.20US$6,400Apr 24, 2026
Levine Zurit
Officer: SVP, Business Development
Sale2,000USD 2.80US$5,600Apr 14, 2026
Ophir Eran
Director, Officer: President and CEO
Sale5,000USD 2.90US$14,500Apr 14, 2026
Levine Zurit
Officer: SVP, Business Development
Sale3,125USD 2.56US$8,000Apr 10, 2026
Levine Zurit
Officer: SVP, Business Development
Sale5,375USD 2.42US$13,008Apr 8, 2026
Levine Zurit
Officer: SVP, Business Development
Sale2,500USD 2.30US$5,750Apr 7, 2026
Ophir Eran
Director, Officer: President and CEO
Sale5,625USD 2.21US$12,431Apr 1, 2026
Levine Zurit
Officer: SVP, Business Development
Sale3,500USD 2.20US$7,700Apr 1, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Sanford S Zweifach
Other companies: Carisma Therapeutics, Inc. (Director · Mar 7, 2023 – Jun 26, 2024 · Past); ESSA Pharma Inc (Director · Oct 1, 2020 – Mar 25, 2024 · Past); Anthera Pharmaceuticals Inc (Director · Mar 25, 2013 – May 21, 2015 · Past)
Director · Since at least Mar 18, 2026
David Silberman
Other companies: Nasus Pharma Ltd. (Board Member · Since at least Mar 18, 2026); Oramed Pharmaceuticals Inc. (Chief Financial Officer · Jul 5, 2021 – Jan 4, 2024 · Past)
Chief Financial Officer · Since at least Mar 18, 2026
Michele Holcomb
Other companies: Kimball Electronics, Inc. (Director · Since at least Nov 7, 2019); Cardinal Health, Inc. (EVP - Strategy & Corp. Dev. · Jan 3, 2017 – Aug 15, 2022 · Past)
Director · Since at least Feb 12, 2026
Anat Cohen-Dayag
Other companies: Gamida Cell Ltd (Director · Jan 28, 2022 – Feb 8, 2023 · Past)
Executive Chair · Since at least Mar 2, 2026
Dorit AmitayVice President, Human Resources · Since at least Nov 5, 2026
Eran Ben DorGeneral Counsel and Corporate Secretary · Since at least Nov 5, 2026
Eran OphirPresident and CEO · Since at least Mar 18, 2026
Eran PerryManaging Director and Chairman of the Investment Committee, MII Fund & Labs · Since at least Mar 18, 2026
Gilead HalevyDirector · Since at least Mar 18, 2026
Lindsey TrickettHead of Investor Relations and Corporate Communications · Since at least Nov 3, 2026
All 18 people
PersonSeat
Mathias HukkelhovenDirector · Since at least Jul 29, 2026
Michelle MahlerChief Medical Officer · Since at least Mar 18, 2026
Pierre FerreChief Operating Officer · Since at least Mar 18, 2026
Russo Sharon KredoSVP, Research & Discovery · Since at least Mar 18, 2026
Savitzky Kinneret LivnatDirector · Since at least Mar 18, 2026
Sharon Kredo-RussoSenior Vice President, Research & Discovery · Since at least Nov 5, 2026
Yvonne NaughtonPh.D.Vice President, Head of Investor Relations and Corporate CommunicationsEmail · Since at least Dec 17, 2025
Zurit LevineSenior Vice President, Business Development · Since at least Mar 18, 2026

Open People

Log in to ask 6ix AI your own questions about Compugen Ltd.